公开(公告)号：US09920036B2

公开(公告)日：2018-03-20

申请号：US15127051

申请日：2015-03-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: A61K31/343 ,  C07D307/84 ,  A61P31/14 ,  A61K31/506 ,  C07D413/10 ,  C07D405/10

CPC classification number: C07D405/10 ,  A61K31/343 ,  A61K31/506 ,  C07D307/84 ,  C07D413/10

Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I).

公开(公告)号：US09914739B2

公开(公告)日：2018-03-13

申请号：US15127054

申请日：2015-03-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D491/048 ,  C07B59/00

CPC classification number: C07D491/048 ,  C07B59/002 ,  C07B2200/05

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US20170217989A1

公开(公告)日：2017-08-03

申请号：US15515170

申请日：2015-10-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D498/22 ,  C07D498/04 ,  C07D493/14 ,  C07D493/04

CPC classification number: C07D498/22 ,  C07D493/04 ,  C07D493/14 ,  C07D498/04

Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US20170174667A1

公开(公告)日：2017-06-22

申请号：US15127051

申请日：2015-03-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D405/10 ,  A61K31/343 ,  A61K31/506 ,  C07D413/10 ,  C07D307/84

CPC classification number: C07D405/10 ,  A61K31/343 ,  A61K31/506 ,  C07D307/84 ,  C07D413/10

Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I)

公开(公告)号：US09505752B2

公开(公告)日：2016-11-29

申请号：US14419559

申请日：2013-08-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow ,  Nicholas A. Meanwell ,  Edward H. Ruediger ,  Clint A. James ,  Daniel H. Deon ,  David J. Carini ,  Barry L. Johnson

IPC: C07D471/04 ,  A61K31/4545 ,  C07D401/06 ,  A61K31/454 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D401/06

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors.

公开(公告)号：US20160152615A1

公开(公告)日：2016-06-02

申请号：US15015712

申请日：2016-02-04

Applicant: Bristol-Myers Squibb Company

Inventor： TAO WANG ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

公开(公告)号：US09326973B2

公开(公告)日：2016-05-03

申请号：US13735224

申请日：2013-01-07

Applicant: Bristol-Myers Squibb Company

Inventor： Piyasena Hewawasam ,  John F. Kadow ,  Omar D. Lopez ,  Nicholas A. Meanwell ,  Yong Tu ,  Alan Xiangdong Wang ,  Ningning Xu ,  Samayamunthula Venkata Satya Arun Kumar Gupta ,  Pothukanuri Srinivasu ,  Indasi Gopi Kumar ,  Ponugupati Suresh Kumar ,  Makonen Belema ,  Robert A. Fridell ,  Min Gao ,  Julie A. Lemm ,  Donald R. O'Boyle, II ,  Jin-Hua Sun ,  Chunfu Wang ,  Ying-Kai Wang

IPC: A61K31/415 ,  A61K31/675 ,  A61K38/00 ,  A61K31/4178 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/21 ,  A61K45/06 ,  C07D403/14 ,  C07D491/113

CPC classification number: A61K31/4178 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217 ,  A61K45/06 ,  C07D403/14 ,  C07D491/113 ,  A61K2300/00

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract translation: 本公开通常涉及抗病毒化合物，更具体地涉及可以抑制丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物的组合，包含这些组合的组合物，以及用于抑制NS5A的功能的方法 蛋白。

公开(公告)号：US20150344492A1

公开(公告)日：2015-12-03

申请号：US14759684

申请日：2014-01-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D491/06

CPC classification number: C07D491/06 ,  A61K31/343 ,  C07D307/84 ,  C07D491/04 ,  C07D498/04

Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 阐述了式I化合物，包括它们的盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US09193720B2

公开(公告)日：2015-11-24

申请号：US14619438

申请日：2015-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： B. Narasimhulu Naidu ,  Manoj Patel ,  Jeffrey Lee Romine ,  Denis R. St. Laurent ,  Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D213/24 ,  A61K31/00 ,  C07D417/14 ,  C07D401/04 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

CPC classification number: C07D417/14 ,  C07D213/61 ,  C07D401/04 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract translation: 本公开一般涉及式I，II，III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。

公开(公告)号：US20150315218A1

公开(公告)日：2015-11-05

申请号：US14800315

申请日：2015-07-15

Applicant: Bristol-Myers Squibb Company

Inventor： Yasutsugu Ueda ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC: C07F9/6561

CPC classification number: A61K31/675 ,  A61K31/497 ,  A61K31/519 ,  A61K45/06 ,  C07C215/10 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection: wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途：其中：X为C或N，条件是当X为N时，不存在R1; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自其中：L和M独立地选自C1-C6烷基，苯基，苄基，三烷基甲硅烷基，-2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。